CW
CUE icon

Channel Wealth’s Cue Biopharma CUE Stock Holding History

Channel Wealth’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-510
Closed -$35.2K – 183
2023
Q3 		$35.2K Sell
510
-1,780
-78% -$174K 0.02% 177
2023
Q2 		$251K Buy
2,290
+288
+14% +$33.8K 0.14% 152
2023
Q1 		$214K Buy
+2,002
New +$191K 0.14% 179

Other funds holding CUE

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Channel Wealth's CUE Position: Q4 2023 in Review

Channel Wealth sold out of Cue Biopharma (CUE) in Q4 2023, closing a stake of 510 shares — an estimated $35.2K sold.

Channel Wealth first reported a position in CUE in Q1 2023 and held it in 3 quarters. The position peaked at $251K in Q2 2023. 80 funds tracked by Wall St. Rank hold CUE as of Q4 2023.

  • Channel Wealth reported no remaining Cue Biopharma position as of Q4 2023 after selling out during the quarter.
  • Channel Wealth sold 510 Cue Biopharma shares in Q4 2023, an estimated $35.2K.
  • Channel Wealth first reported a position in Cue Biopharma in Q1 2023 and held it in 3 quarters.
  • Channel Wealth's Cue Biopharma position peaked at $251K in Q2 2023.
  • 80 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2023.

Based on Channel Wealth's 13F filing for Q4 2023, filed 8 Jan 2024.